Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$25.86
-2.4%
$24.04
$14.80
$40.47
$1.97B0.86837,930 shs626,383 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.97
-1.1%
$32.24
$26.47
$41.61
$1.89B0.87623,932 shs786,752 shs
Opthea Limited stock logo
OPT
Opthea
$3.41
$3.41
$1.79
$6.30
$524.84M1.1226,617 shsN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$33.52
-0.3%
$34.05
$27.12
$60.90
$2.01B2.38976,408 shs737,672 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%-3.90%+2.01%-6.98%-27.18%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.00%-7.39%-3.68%+0.76%+11.95%
Opthea Limited stock logo
OPT
Opthea
0.00%0.00%0.00%+7.23%+36.40%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.00%+6.18%+11.36%-16.12%-36.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.4606 of 5 stars
4.51.00.00.02.90.80.0
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.7683 of 5 stars
4.61.00.00.03.53.34.4
Opthea Limited stock logo
OPT
Opthea
0.7083 of 5 stars
2.10.00.00.01.50.80.6
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.1128 of 5 stars
4.41.00.04.42.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.00
Buy$58.22125.14% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.11
Buy$53.0060.75% Upside
Opthea Limited stock logo
OPT
Opthea
2.17
Hold$1.33-60.90% Downside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4050.36% Upside

Current Analyst Ratings Breakdown

Latest OPT, CGON, HRMY, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$61.00
5/19/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.00
5/15/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.00
5/13/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/2/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$41.00
4/29/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$662K2,977.61N/AN/A($1.94) per share-13.33
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$744.85M2.54$2.46 per share13.38$7.97 per share4.14
Opthea Limited stock logo
OPT
Opthea
$87.67K5,986.77N/AN/A($0.56) per share-6.09
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.78N/AN/A$7.64 per share4.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$48.61M-$1.51N/AN/AN/A-10,642.98%-18.97%-15.36%8/14/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$128.85M$2.6215.6310.600.4717.98%23.16%14.24%8/5/2025 (Estimated)
Opthea Limited stock logo
OPT
Opthea
-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)

Latest OPT, CGON, HRMY, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
3/25/2025Q4 2024
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Opthea Limited stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
35.32
35.32
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.28
3.24
3.20
Opthea Limited stock logo
OPT
Opthea
N/A
2.94
2.94
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Opthea Limited stock logo
OPT
Opthea
55.95%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
7.40%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
23.60%
Opthea Limited stock logo
OPT
Opthea
3.20%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.23 millionN/AOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million39.47 millionOptionable
Opthea Limited stock logo
OPT
Opthea
8153.91 million148.98 millionNot Optionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CG Oncology stock logo

CG Oncology NASDAQ:CGON

$25.86 -0.64 (-2.42%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$26.92 +1.06 (+4.11%)
As of 06/13/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$32.97 -0.36 (-1.08%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.02 +0.05 (+0.14%)
As of 06/13/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)
As of 06/13/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.52 -0.11 (-0.33%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.51 -0.02 (-0.04%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.